For patients who want FDA-approved, brand-name GLP-1 medications — not compounded alternatives — the pricing picture in 2026 is complex. List prices remain high, insurance coverage is inconsistent, and the savings programs that make these medications affordable aren't available to everyone.
Here's the complete breakdown of what Wegovy and Zepbound actually cost in 2026, through every available channel.
Brand-Name List Prices
| Medication | Manufacturer | Monthly List Price (approx) | Indication |
|---|---|---|---|
| Wegovy (injectable) | Novo Nordisk | ~$1,350/mo | Weight management |
| Oral Wegovy | Novo Nordisk | ~$1,300–1,400/mo | Weight management |
| Zepbound | Eli Lilly | ~$1,060/mo | Weight management |
| Ozempic | Novo Nordisk | ~$935/mo | Type 2 diabetes |
| Mounjaro | Eli Lilly | ~$1,060/mo | Type 2 diabetes |
Important context: Very few patients actually pay list price. The real cost depends on insurance coverage, manufacturer savings programs, and the pharmacy you use. The sections below break down each pathway to lower costs.
Insurance Coverage in 2026
Insurance coverage for GLP-1 weight loss medications has expanded significantly, but it's far from universal. Here's the current landscape:
Medicare: As of 2026, Medicare has begun covering GLP-1 medications for weight loss under certain conditions, a major policy shift. Coverage details and qualifying criteria vary — check with your Medicare plan for specifics.
Private insurance: Coverage varies dramatically by plan. Many employer-sponsored plans now include GLP-1 coverage for weight management, often with prior authorization requirements. Some plans cover only the diabetes indications (Ozempic/Mounjaro), not the weight management versions (Wegovy/Zepbound).
Typical insured costs: Patients with coverage generally pay $25–$300/month in copays or coinsurance, depending on their plan's formulary tier and benefit design.
Without coverage: Patients without GLP-1 insurance coverage face list prices unless they qualify for manufacturer savings programs or use alternative channels.
Manufacturer Savings Programs
Novo Nordisk (Wegovy) Savings
Novo Nordisk offers savings programs for eligible commercially insured patients. These programs can reduce out-of-pocket costs significantly — in some cases to as low as $0 for the first months, with copay caps thereafter. Eligibility typically excludes patients on government insurance (Medicare, Medicaid, Tricare).
Eli Lilly (Zepbound) Savings
Eli Lilly has offered various savings programs for Zepbound, including direct-to-consumer pricing options through their LillyDirect platform. These programs have varied in availability and pricing structure throughout 2025–2026. Check Lilly's current offerings directly for the latest programs.
Important Limitations
Manufacturer savings programs typically require commercial insurance (not Medicare/Medicaid), may have income limits, and often expire after a set period (6–12 months). They can be excellent short-term solutions but aren't guaranteed to continue indefinitely.
Cash-Pay Options for Brand-Name Medications
For patients paying cash without insurance coverage, several options can reduce brand-name costs:
Telehealth platforms offering brand-name access. Some telehealth providers have negotiated pricing for brand-name GLP-1 medications that's lower than retail pharmacy list prices. Sesame Care is one platform offering access to FDA-approved brand-name medications.
Sesame Care provides access to FDA-approved brand-name GLP-1 medications including Wegovy and Zepbound, potentially at pricing below standard retail.
View Sesame Care →Pharmacy discount programs. GoodRx, RxSaver, and similar platforms may offer discount pricing on brand-name GLP-1 medications at participating pharmacies. Savings vary widely by pharmacy and location.
International pharmacy options. Some patients explore international pharmacies for lower prices on brand-name GLP-1 medications. This involves regulatory and safety considerations that are beyond the scope of this guide — discuss with your healthcare provider.
Brand-Name vs Compounded: The Full Price Picture
| Pathway | Monthly Cost | FDA Approved? | Who Qualifies |
|---|---|---|---|
| Brand-name with savings program | $0–$25/mo | Yes | Commercially insured, eligible |
| Brand-name with insurance | $25–$300/mo | Yes | Patients with GLP-1 coverage |
| Brand-name cash pay | $935–$1,400/mo | Yes | Anyone (no restrictions) |
| Compounded (telehealth) | $146–$400/mo | No | Anyone with prescription |
The takeaway: If you qualify for manufacturer savings programs or have strong insurance coverage, brand-name medications can be surprisingly affordable. If you don't, the price gap between brand-name ($935–$1,400/mo) and compounded ($146–$400/mo) makes compounded alternatives the practical choice for most cash-pay patients.
Compounded Alternatives for Cash-Pay Patients
For patients who can't access affordable brand-name pricing, compounded GLP-1 medications offer effective treatment at a fraction of the cost. These providers offer some of the most competitive compounded pricing:
How to Navigate Your Best Path
Step 1: Check your insurance formulary for Wegovy and Zepbound coverage. Call the number on your insurance card and ask specifically about GLP-1 coverage for weight management.
Step 2: If covered, check manufacturer savings programs to see if you qualify for additional copay reduction.
Step 3: If not covered (or if copays are still too high), compare compounded options using our Price Index.
Step 4: Regardless of which path you choose, use HSA/FSA funds if available — the tax savings apply to both brand-name and compounded medications. See our HSA/FSA guide.
Bottom line: Brand-name Wegovy and Zepbound remain the gold standard for FDA-approved GLP-1 weight loss treatment. But access depends heavily on your insurance status and eligibility for savings programs. For cash-pay patients, compounded alternatives offer the same active ingredients at 75–90% lower cost from legitimate telehealth providers.